ArticleBritish journal of haematology2023

Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?

Luis Carlos Saiz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.